Maurer-Stroh S - Search Results

1

Investigation of causes of oseltamivir chemoprophylaxis failures during influenza A (H1N1-2009) outbreaks.

Lee VJ, Yap J, Maurer-Stroh S, Lee RT, Eisenhaber F, Tay JK, Ting PJ, Loh JP, Wong CW, Tan BH, Koay ES, Kelly PM, Hibberd ML. Lee VJ, et al. J Clin Virol. 2011 Feb;50(2):104-8. doi: 10.1016/j.jcv.2010.10.004. Epub 2010 Nov 19. J Clin Virol. 2011. PMID: 21094080

2

Emergence of oseltamivir-resistant pandemic (H1N1) 2009 virus within 48 hours.

Inoue M, Barkham T, Leo YS, Chan KP, Chow A, Wong CW, Tze Chuen Lee R, Maurer-Stroh S, Lin R, Lin C. Inoue M, et al. Emerg Infect Dis. 2010 Oct;16(10):1633-6. doi: 10.3201/eid1610.100688. Emerg Infect Dis. 2010. PMID: 20875299 Free PMC article.

3

All that glitters is not gold--founder effects complicate associations of flu mutations to disease severity.

Lee RT, Santos CL, de Paiva TM, Cui L, Sirota FL, Eisenhaber F, Maurer-Stroh S. Lee RT, et al. Virol J. 2010 Nov 1;7:297. doi: 10.1186/1743-422X-7-297. Virol J. 2010. PMID: 21040570 Free PMC article.

4

The highly pathogenic H7N3 avian influenza strain from July 2012 in Mexico acquired an extended cleavage site through recombination with host 28S rRNA.

Maurer-Stroh S, Lee RT, Gunalan V, Eisenhaber F. Maurer-Stroh S, et al. Virol J. 2013 May 1;10:139. doi: 10.1186/1743-422X-10-139. Virol J. 2013. PMID: 23635025 Free PMC article.

5

Mapping the sequence mutations of the 2009 H1N1 influenza A virus neuraminidase relative to drug and antibody binding sites.

Maurer-Stroh S, Ma J, Lee RT, Sirota FL, Eisenhaber F. Maurer-Stroh S, et al. Biol Direct. 2009 May 20;4:18; discussion 18. doi: 10.1186/1745-6150-4-18. Biol Direct. 2009. PMID: 19457254 Free PMC article.

6

A new common mutation in the hemagglutinin of the 2009 (H1N1) influenza A virus.

Maurer-Stroh S, Lee RT, Eisenhaber F, Cui L, Phuah SP, Lin RT. Maurer-Stroh S, et al. PLoS Curr. 2010 Jun 1;2:RRN1162. doi: 10.1371/currents.rrn1162. PLoS Curr. 2010. PMID: 20535229 Free PMC article.

7

Utilising animal models to evaluate oseltamivir efficacy against influenza A and B viruses with reduced in vitro susceptibility.

Farrukee R, Tai CM, Oh DY, Anderson DE, Gunalan V, Hibberd M, Lau GY, Barr IG, Messling VV, Maurer-Stroh S, Hurt AC. Farrukee R, et al. PLoS Pathog. 2020 Jun 18;16(6):e1008592. doi: 10.1371/journal.ppat.1008592. eCollection 2020 Jun. PLoS Pathog. 2020. PMID: 32555740 Free PMC article.

8

Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses.

Butler J, Hooper KA, Petrie S, Lee R, Maurer-Stroh S, Reh L, Guarnaccia T, Baas C, Xue L, Vitesnik S, Leang SK, McVernon J, Kelso A, Barr IG, McCaw JM, Bloom JD, Hurt AC. Butler J, et al. PLoS Pathog. 2014 Apr 3;10(4):e1004065. doi: 10.1371/journal.ppat.1004065. eCollection 2014 Apr. PLoS Pathog. 2014. PMID: 24699865 Free PMC article.

9

Comparison of microarray-predicted closest genomes to sequencing for poliovirus vaccine strain similarity and influenza A phylogeny.

Maurer-Stroh S, Lee CW, Patel C, Lucero M, Nohynek H, Sung WK, Murad C, Ma J, Hibberd ML, Wong CW, Simões EA. Maurer-Stroh S, et al. Diagn Microbiol Infect Dis. 2016 Mar;84(3):203-6. doi: 10.1016/j.diagmicrobio.2015.11.003. Epub 2015 Nov 6. Diagn Microbiol Infect Dis. 2016. PMID: 26658310 Free article.

10

HIV-1 adaptation to low levels of CCR5 results in V3 and V2 loop changes that increase envelope pathogenicity, CCR5 affinity and decrease susceptibility to Maraviroc.

Garg H, Lee RT, Maurer-Stroh S, Joshi A. Garg H, et al. Virology. 2016 Jun;493:86-99. doi: 10.1016/j.virol.2016.03.010. Epub 2016 Mar 24. Virology. 2016. PMID: 27017055 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

221 results

Search Page

Filters